Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 2 relugolix phase 3 study in women with endometriosis-associated pain
2017-001632-19Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tissue-plasminogen activator in endometriosis (3 arms), sponsored by Myovant Sciences. Primary endpoint: Dysmenorrhea responder rate at Week 24/EOT. Started Jul 2017; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2017-001632-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001632-19.